Metabolon

Metabolon Wins National Institute of Health (NIH) Award to Develop Test to Improve Polycystic Ovary Syndrome (PCOS) Diagnostic Accuracy

Retrieved on: 
Tuesday, December 5, 2023
Classification, Woman, Associate, Polycystic ovary syndrome, Patient, Research and development, Medicine, Infertility, PCOS, NIH, Biomarker, Today, Publication, Metabolomics, Medical imaging, Birth control, Research, Metabolon

MORRISVILLE, N.C., Dec. 5, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced receipt of a National Institute of Health (NIH) award to improve the accuracy by which polycystic ovary syndrome (PCOS) can be diagnosed.

Key Points: 
  • PCOS is the most common cause of infertility worldwide, affecting an estimated 8-13% of women of childbearing age.
  • Current diagnoses typically require pelvic exams and blood tests to obtain a hormone profile, glucose tolerance, and lipid measurements.
  • This diagnostic algorithm likely misclassifies or outright misses a lot of cases," said Adam Kennedy, Associate Director of Research and Development at Metabolon.
  • "Metabolon's work in this area will potentially bring PCOS diagnostic guidelines into the 21st century using highly advanced, cutting-edge metabolomics science."

Metabolon Collaborates with Trajan on Microsampling Solutions for Metabolomics Research

Retrieved on: 
Monday, November 20, 2023
Research, Collection, Clinical trial, Trajan, Patient, Medicine, Mitra, Health, Partnership, Metabolomics, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C. and TORRANCE, Calif., Nov. 20, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, and Trajan Scientific and Medical, creator of Neoteryx Mitra® biological sample collection devices based on VAMS® technology, announce a partnership to collaborate on microsampling solutions for metabolomics research.   

Key Points: 
  • MORRISVILLE, N.C. and TORRANCE, Calif., Nov. 20, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, and Trajan Scientific and Medical, creator of Neoteryx Mitra® biological sample collection devices based on VAMS® technology, announce a partnership to collaborate on microsampling solutions for metabolomics research.
  • Life science research studies are frequently constrained by their inability to easily and efficiently secure adequate, stable biological samples.
  • Mitra devices offer precision via a volumetric absorptive microsampling method that is minimally invasive and user-friendly.
  • To learn more about metabolomics and how Metabolon is partnering with Trajan to take advantage of Neoteryx Mitra collection devices based on VAMS technology, please visit the Metabolon website or Neoteryx website .

Metabolon Collaborates with Trajan on Microsampling Solutions for Metabolomics Research

Retrieved on: 
Monday, November 20, 2023
Research, Collection, Clinical trial, Trajan, Patient, Medicine, Mitra, Health, Partnership, Metabolomics, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C. and TORRANCE, Calif., Nov. 20, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, and Trajan Scientific and Medical, creator of Neoteryx Mitra® biological sample collection devices based on VAMS® technology, announce a partnership to collaborate on microsampling solutions for metabolomics research.

Key Points: 
  • MORRISVILLE, N.C. and TORRANCE, Calif., Nov. 20, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, and Trajan Scientific and Medical, creator of Neoteryx Mitra® biological sample collection devices based on VAMS® technology, announce a partnership to collaborate on microsampling solutions for metabolomics research.
  • Life science research studies are frequently constrained by their inability to easily and efficiently secure adequate, stable biological samples.
  • Mitra devices offer precision via a volumetric absorptive microsampling method that is minimally invasive and user-friendly.
  • To learn more about metabolomics and how Metabolon is partnering with Trajan to take advantage of Neoteryx Mitra collection devices based on VAMS technology, please visit the Metabolon website or Neoteryx website .

Metabolon and Genomics England Announce Partnership to Characterize Hundreds of Rare Diseases and Advance Rare Disease Diagnosis

Retrieved on: 
Wednesday, October 25, 2023
Science, Genomics, Rare disease, Biomarker, Life, Mortality, Data, Research, Quality of life, NHS, Medicine, Partnership, England, NHS England, Metabolomics, Cancer, Patient, Diagnosis, Genomics England, 100,000 Genomes Project, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., and LONDON, Oct. 25, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, and Genomics England, a UK government-funded organization holding one of the world's largest rare disease datasets, today announce a collaboration to further characterize hundreds of rare diseases to advance the field of rare disease diagnosis. 

Key Points: 
  • Rare diseases are incredibly difficult to analyze and can often take years to obtain a definitive diagnosis, if at all.
  • Metabolon's proprietary precision medicine platform and tools have demonstrated clinical utility for diagnosis, treatment guidance, and monitoring of individuals suffering from rare diseases.
  • It is hoped this research collaboration between Metabolon and Genomics England will enable the rapid discovery of novel biomarkers for known rare diseases and uncover disease-causing pathways for many unknown rare diseases.
  • "We are thrilled to partner with Genomics England to improve the diagnosis of patients with rare disease."

Metabolon and Genomics England Announce Partnership to Characterize Hundreds of Rare Diseases and Advance Rare Disease Diagnosis

Retrieved on: 
Wednesday, October 25, 2023
Science, Genomics, Rare disease, Biomarker, Life, Mortality, Data, Research, Quality of life, NHS, Medicine, Partnership, England, NHS England, Metabolomics, Cancer, Patient, Diagnosis, Genomics England, 100,000 Genomes Project, Pharmaceutical industry, Metabolon

MORRISVILLE, N.C., and LONDON, Oct. 25, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, and Genomics England, a UK government-funded organization holding one of the world's largest rare disease datasets, today announce a collaboration to further characterize hundreds of rare diseases to advance the field of rare disease diagnosis. 

Key Points: 
  • Rare diseases are incredibly difficult to analyze and can often take years to obtain a definitive diagnosis, if at all.
  • Metabolon's proprietary precision medicine platform and tools have demonstrated clinical utility for diagnosis, treatment guidance, and monitoring of individuals suffering from rare diseases.
  • It is hoped this research collaboration between Metabolon and Genomics England will enable the rapid discovery of novel biomarkers for known rare diseases and uncover disease-causing pathways for many unknown rare diseases.
  • "We are thrilled to partner with Genomics England to improve the diagnosis of patients with rare disease."

Metabolon Launches New Liver Fibrosis and Kidney Function Discovery Panels to Reveal Disease Mechanisms and Facilitate Research

Retrieved on: 
Thursday, October 12, 2023
Medicine, Biomarker, Metabolomics, Liver, Death, Patient, Chronic liver disease, Chronic kidney disease, Lipid metabolism, Cirrhosis, Drug discovery, Kidney disease, Research, Dietary supplement, Metabolon

MORRISVILLE, N.C., Oct. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announces the launch of its new Liver Fibrosis and Kidney Function Discovery Panels.

Key Points: 
  • As part of the Metabolon Discover portfolio of metabolomics services, Metabolon's new Liver Fibrosis and Kidney Function Discovery Panels assess multiple metabolites across diverse biological pathways associated with liver fibrosis and kidney disease, providing a greater understanding of these conditions.
  • Metabolon's Kidney Function Discovery Panel analyzes 84 metabolites associated with biochemical processes affecting kidney function to help researchers differentiate the diverse spectrum of kidney disease.
  • "Our new Liver Fibrosis and Kidney Function Discovery Panels seek to reveal fundamental metabolic changes, thereby facilitating our understanding of the underlying mechanisms of these diseases," said Rangaprasad (Ranga) Sarangarajan, Ph.D., Chief Scientific Officer at Metabolon.
  • To learn more about how Metabolon can help you gain functional insights into liver and kidney disease, please visit our Liver Fibrosis Discovery Panel and Kidney Function Discovery Panel pages.

Metabolon Launches New Liver Fibrosis and Kidney Function Discovery Panels to Reveal Disease Mechanisms and Facilitate Research

Retrieved on: 
Thursday, October 12, 2023
Medicine, Biomarker, Metabolomics, Liver, Death, Patient, Chronic liver disease, Chronic kidney disease, Lipid metabolism, Cirrhosis, Drug discovery, Kidney disease, Research, Dietary supplement, Metabolon

MORRISVILLE, N.C., Oct. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announces the launch of its new Liver Fibrosis and Kidney Function Discovery Panels.

Key Points: 
  • As part of the Metabolon Discover portfolio of metabolomics services, Metabolon's new Liver Fibrosis and Kidney Function Discovery Panels assess multiple metabolites across diverse biological pathways associated with liver fibrosis and kidney disease, providing a greater understanding of these conditions.
  • Metabolon's Kidney Function Discovery Panel analyzes 84 metabolites associated with biochemical processes affecting kidney function to help researchers differentiate the diverse spectrum of kidney disease.
  • "Our new Liver Fibrosis and Kidney Function Discovery Panels seek to reveal fundamental metabolic changes, thereby facilitating our understanding of the underlying mechanisms of these diseases," said Rangaprasad (Ranga) Sarangarajan, Ph.D., Chief Scientific Officer at Metabolon.
  • To learn more about how Metabolon can help you gain functional insights into liver and kidney disease, please visit our Liver Fibrosis Discovery Panel and Kidney Function Discovery Panel pages.

IDEX Biometrics appoints new Chief Financial Officer

Retrieved on: 
Monday, September 25, 2023
IDEX Biometrics, CFO, Interim, Metabolon, CREE, Interim management, Semiconductor, Cirrus Logic, Strategic planning, Management

Oslo, Norway, 25 September 2023 - IDEX Biometrics has appointed John T. Kurtzweil as Chief Financial Officer effective today.

Key Points: 
  • Oslo, Norway, 25 September 2023 - IDEX Biometrics has appointed John T. Kurtzweil as Chief Financial Officer effective today.
  • He joins IDEX Biometrics after having served as CFO at Metabolon, a US life science company, where he was pivotal in revitalizing the company.
  • Mr. Kurtzweil succeeds Eileen Wynne who has been Interim CFO in IDEX Biometrics since August 2022.
  • Vince Graziani, Chief Executive Officer of IDEX Biometrics, comments: “We welcome John Kurtzweil to our global executive team.

Metabolon Launches New Biological Stress Discovery Panel to Aid Detection of Inflammation and Biological Stress Biomarkers

Retrieved on: 
Tuesday, September 12, 2023
Injury, Infection, Inflammation, Research and development, Intricate Vengeance, Oxidative stress, Metabolism, Metabolomics, Medicine, Aquaculture, Pharmaceutical industry, Nursing, Metabolon, Research

MORRISVILLE, N.C., Sept. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announces the launch of its new Biological Stress Discovery Panel.

Key Points: 
  • Metabolon's new Biological Stress Discovery Panel supports inflammation, immune function, and stress research with advanced analytics
    MORRISVILLE, N.C., Sept. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announces the launch of its new Biological Stress Discovery Panel.
  • Part of the Metabolon Discover portfolio of metabolomics services, the Biological Stress Discovery Panel encompasses 114 metabolites strongly associated with chronic stress and provides insights into various biological stress pathways, including inflammation, injury, circulation, and oxidative stress.
  • The Biological Stress Discovery Panel incorporates new visualization tools and allows researchers to compare results across different data sets to identify statistically significant changes in metabolite abundance.
  • To learn more about how Metabolon can help you discover biological stressors and pathways, please visit our Biological Stress Discovery Panel page.

Metabolon Launches New Biological Stress Discovery Panel to Aid Detection of Inflammation and Biological Stress Biomarkers

Retrieved on: 
Tuesday, September 12, 2023
Injury, Infection, Inflammation, Research and development, Intricate Vengeance, Oxidative stress, Metabolism, Metabolomics, Medicine, Aquaculture, Pharmaceutical industry, Nursing, Metabolon, Research

MORRISVILLE, N.C., Sept. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announces the launch of its new Biological Stress Discovery Panel.

Key Points: 
  • Metabolon's new Biological Stress Discovery Panel supports inflammation, immune function, and stress research with advanced analytics
    MORRISVILLE, N.C., Sept. 12, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announces the launch of its new Biological Stress Discovery Panel.
  • Part of the Metabolon Discover portfolio of metabolomics services, the Biological Stress Discovery Panel encompasses 114 metabolites strongly associated with chronic stress and provides insights into various biological stress pathways, including inflammation, injury, circulation, and oxidative stress.
  • The Biological Stress Discovery Panel incorporates new visualization tools and allows researchers to compare results across different data sets to identify statistically significant changes in metabolite abundance.
  • To learn more about how Metabolon can help you discover biological stressors and pathways, please visit our Biological Stress Discovery Panel page.